Skip to main content
. Author manuscript; available in PMC: 2020 May 4.
Published in final edited form as: Biometrics. 2019 Sep 19;76(1):304–315. doi: 10.1111/biom.13116

Figure 1.

Figure 1.

Average total number of patients overdosed, i.e. treated with a regime having true πc,rT>π¯T=.15 in scenarios 1–6 and πc,rT>π¯T=.30 in scenarios 7–8, for the TD (circle o), ITD (triangle Δ), TDC (plus +), and TDU (cross ×) under the simulation scenarios in Table 1. “TD” is the proposed two-stage trial design; “TDC” denotes the two-stage trial design based on complete (YT, YE) data; “TDU” denotes the two-stage trial design based on AR probabilities ωc(d,s); “ITD” denotes the independent two-stage design that conducts a separate regime-finding trial for each subgroup.